LSB Valuation

LakeShore Biopharma Co Ltd

Add to Watchlist

Advanced Chart

0.820

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

LSB Relative Valuation

LSB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LSB is overvalued; if below, it's undervalued.

Historical Valuation

LakeShore Biopharma Co Ltd (LSB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.16 is considered Undervalued compared with the five-year average of -1.33. The fair price of LakeShore Biopharma Co Ltd (LSB) is between 6.19 to 8.36 according to relative valuation methord. Compared to the current price of 0.82 USD , LakeShore Biopharma Co Ltd is Undervalued By 86.76%.

Relative Value

Fair Zone

6.19-8.36

Current Price：0.82

86.76%

Undervalued

2.15

Trailing

Forward

5.38

EV/EBITDA

LakeShore Biopharma Co Ltd. (LSB) has a current EV/EBITDA of 5.38. The 5-year average EV/EBITDA is -32.01. The thresholds are as follows: Strongly Undervalued below -121.67, Undervalued between -121.67 and -76.84, Fairly Valued between 12.82 and -76.84, Overvalued between 12.82 and 57.65, and Strongly Overvalued above 57.65. The current Forward EV/EBITDA of 5.38 falls within the Historic Trend Line -Fairly Valued range.

21.15

EV/EBIT

LakeShore Biopharma Co Ltd. (LSB) has a current EV/EBIT of 21.15. The 5-year average EV/EBIT is -2.64. The thresholds are as follows: Strongly Undervalued below -11.08, Undervalued between -11.08 and -6.86, Fairly Valued between 1.57 and -6.86, Overvalued between 1.57 and 5.79, and Strongly Overvalued above 5.79. The current Forward EV/EBIT of 21.15 falls within the Strongly Overvalued range.

0.16

LakeShore Biopharma Co Ltd. (LSB) has a current PS of 0.16. The 5-year average PS is 0.55. The thresholds are as follows: Strongly Undervalued below -0.57, Undervalued between -0.57 and -0.01, Fairly Valued between 1.11 and -0.01, Overvalued between 1.11 and 1.67, and Strongly Overvalued above 1.67. The current Forward PS of 0.16 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

LakeShore Biopharma Co Ltd. (LSB) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.

0.00

P/FCF

LakeShore Biopharma Co Ltd. (LSB) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

LakeShore Biopharma Co Ltd (LSB) has a current Price-to-Book (P/B) ratio of 0.23. Compared to its 3-year average P/B ratio of -15.95 , the current P/B ratio is approximately -101.46% higher. Relative to its 5-year average P/B ratio of -30.50, the current P/B ratio is about -100.76% higher. LakeShore Biopharma Co Ltd (LSB) has a Forward Free Cash Flow (FCF) yield of approximately -57.91%. Compared to its 3-year average FCF yield of -56.25%, the current FCF yield is approximately 2.96% lower. Relative to its 5-year average FCF yield of -49.45% , the current FCF yield is about 17.10% lower.

0.23

P/B

Median3y

-15.95

Median5y

-30.50

-57.91

FCF Yield

Median3y

-56.25

Median5y

-49.45

Competitors Valuation Multiple

The average P/S ratio for LSB's competitors is 4.62, providing a benchmark for relative valuation. LakeShore Biopharma Co Ltd Corp (LSB) exhibits a P/S ratio of 0.16, which is -96.56% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LSB.O

LakeShore Biopharma Co Ltd

ProMIS Neurosciences Inc

Akari Therapeutics PLC

Loss

32.61M

PPCB.O

Propanc Biopharma Inc

Performance Decomposition

Market capitalization of LSB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LSB in the past 1 year is driven by Unknown.